• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Lutera is latest birth control recall

News
Article

Actavis is voluntarily recalling more than half a million boxes of Lutera birth control pills because of packaging problems.

Actavis is voluntarily recalling more than half a million boxes of Lutera birth control pills because of packaging problems.

Related: FDA, PatientsLikeMe partner on drug safety data

Allergan’s Actavis is recalling 26 lots, or 511,283 boxes of Lutera because the packaging inserts are out-dated, according to the FDA enforcement report. Patheon manufactured the pills.

While there is no danger to consumers, according to the FDA, 2 other birth control medications have been recalled so far this year. In April, Johnson & Johnson's Janssen recalled a single lot of Ortho-Cept tablets in Canada because of the potential that the potency of the two active ingredients may not meet specifications and be effective.

Related: Pharma needs to be more upfront about drug rejections

Also this spring, Shoppers Drug Mart in Canada said that it mistakenly released some expired packages of Pfizer's Alesse 21 pills. The expired pills might not meet specifications and could result in unwanted pregnancies, according to Health Canada.

Read next: Gilead sues to stop Actavis' generic bid for Letairis

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.